Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|May 27, 2014

EMD Millipore Expands Provantage Upstream Bioproduction Services

EMD Millipore expands its Provantage upstream bioproduction services into North America.

EMD Millipore, the life science division of Merck KGaA, reported the expansion of its upstream services into North America as part of its Provantage biodevelopment and clinical supply offering. The company's Massachusetts facilities will now offer upstream capabilities including media and feed screening, small-scale material production, and optimization of conditions for scale-up and technology transfer.

This expansion allows EMD Millipore's North American customers to access the same services European customers have received at the company's GMP biodevelopment center in Martillac, France.

Source: EMD Millipore


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.